PharmaCyte Biotech Inc (PMCB)

[rudygerner]

Why I'm long PMCB and you should be:

The Cell-in-a-Box®/Melligen cell combo to treat diabetes requires no devices (think ViaCyte), no insulin pumps and no daily insulin injections. No other diabetes treatment comes close.


The four main areas to inject insulin are: abdomen, thigh, hip/buttock and the back of arm - this is where lipohypertrophy and lipodystrophy could obtrude a device location. Insulin injected into the abdomen is absorbed (and therefore put to work) the most quickly. Using the same insulin injection site over and over is not a good idea. Type 1 diabetics are more prone to suffer from lipohypertrophy and lipodystrophy as a result of not rotating insulin injection sites, thereby making a subcutaneous device undesirable.

PharmaCyte's Cell-in-a-Box®/Melligen cell combo to treat diabetes eliminates the need for daily/weekly/monthly insulin injections. It requires no subcutaneous device and elicits no immune response.

Additional problems & complications associated with subcutaneous devices may include: skin abscess (requiring an incision and drainage of the area, and a culture of the fluid), lipohypertrophy and lipodystrophy (more info here on both conditions: http://www.healthline.com/health/diabetes/lipohypertrophy)

More possible side effects from a subcutaneous device could include fixation problems (device movement), resulting in itching/dry skin. People who suffer from eczema could also experience complications with a subcutaneous device.

Another invaluable trait of the The Cell-in-a-Box®/Melligen cell combo, aside from being completely bioinert, is the ability to allow the Melligen cells to secrete insulin without the need for any external devices. These qualities are imperative to achieving an efficacious treatment capable of producing the desired results, while also completely avoiding any immune system response.

PharmaCyte's Cell-in-a-Box®/Melligen cell combo requires no device whatsoever to produce insulin. Furthermore, the insulin-producing Melligen cells are protected from the immune system, thereby avoiding an immune system response. PharmaCyte owns all applicable licenses and patents pertaining to the use of Cell-in-a-Box® to treat diabetes.